Prominent academic brings outstanding track record
to specialty pharma company
Paris, September 14, 2007 - BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, announced today that it has strengthened it R&D team with the appointment of Professor Christian Auclair as Chief Scientific Officer (CSO).
Professor Auclair, 62, PharmD, PhD, a former resident at Hôpitaux de Paris, is currently director of the department of biology at the Ecole Normale Supérieure de Cachan, a leading Paris region university, where he is also director of the Biotechnology and Applied Genetic Pharmacology Laboratory (LBPA) - UMR 8113 CNRS. Prof Auclair is the author of more than 120 publications and is the owner of a number of patents in the field of molecular and cellular pharmacology applied to oncology and virology. He is co-founder and deputy director at the doctoral school of oncology in the faculty of medicine at the university Paris-sud XI and director of the oncology research masters course run jointly by the university of Paris XI and the Ecole Normale Supérieure de Cachan. Professor Auclair is also one of the founders of the Medicen Paris region, designated as pole of competitivity by the French government, where he is responsible for the area of drugs.
He has been a member of BioAlliance Pharma’s scientific board for six years and has introduced a number of innovative projects to the company including the development of HIV-I integrase inhibitors, the development of non-cytotoxic actin cytoskeleton modulators exhibiting anti-invasive properties.
As CSO, Professor Auclair will maintain his academic teaching and research activities while becoming a major participant in the company’s research strategy. He will manage internal working groups involved in priority projects with strategic partners such as CNRS, Inserm, universities, and Institut Gustave Roussy. These working groups form part of BioAlliance’s R&D department, led by Emilienne Soma and Sophie Lebel-Binay. Professor Auclair will also contribute to the company’s scientific communication.
About BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance.
The company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad(R) mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc(R) and acyclovir Lauriad(R)). One product is based on the Transdrug(R) nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug(R)). The company is also developing a New Entities program focused on new targets in oncology and HIV. The company concluded two strategic partnerships in 2007 to sell its Loramyc(R) product in Europe and in the US. Loramyc® has recently been launched on the French market.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.'s website www.bioalliancepharma.com
BioAlliance Pharma SA
President and CEO
Tel : +33 1 45 58 71 00
Tel : +33 1 45 58 76 01 email@example.com
ACTUS Nathalie BOUMENDIL / Agnès GILBERT
Tel : +33 1 53 67 36 36
Andrew Lloyd & Associates
Gilles PETITOT / Juliette DOS SANTOS
Tel : +33 1 56 54 07 07
Tel : +33 1 56 54 07 04
firstname.lastname@example.org / email@example.com
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|ONXEO||Euronext Paris||4.18||-8.33%||1 100 231|